Posdinemab is currently being investigated in the phase 2b AuTonomy study, which enrolled 523 participants with early Alzheimer disease. The Food and Drug Administration (FDA) has granted Fast Track ...
A new large-scale study has mapped the first molecular events that drive the formation of harmful amyloid protein aggregates found in Alzheimer's disease, pointing towards a new potential therapeutic ...
Alzheimer’s disease medicines typically help reduce and manage symptoms. They do not treat the cause of Alzheimer’s disease. Kisunla offers a new approach to treat early Alzheimer’s disease. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback